479 related articles for article (PubMed ID: 25311181)
21. In vivo pharmacokinetics, biodistribution and the anti-tumor effect of cyclic RGD-modified doxorubicin-loaded polymers in tumor-bearing mice.
Wang C; Li Y; Chen B; Zou M
Colloids Surf B Biointerfaces; 2016 Oct; 146():31-8. PubMed ID: 27244048
[TBL] [Abstract][Full Text] [Related]
22. Design and evaluation of pH-sensitive liposomes constructed by poly(2-ethyl-2-oxazoline)-cholesterol hemisuccinate for doxorubicin delivery.
Xu H; Hu M; Yu X; Li Y; Fu Y; Zhou X; Zhang D; Li J
Eur J Pharm Biopharm; 2015 Apr; 91():66-74. PubMed ID: 25660909
[TBL] [Abstract][Full Text] [Related]
23. Liver cancer targeting of Doxorubicin with reduced distribution to the heart using hematoporphyrin-modified albumin nanoparticles in rats.
Chang JE; Shim WS; Yang SG; Kwak EY; Chong S; Kim DD; Chung SJ; Shim CK
Pharm Res; 2012 Mar; 29(3):795-805. PubMed ID: 21971829
[TBL] [Abstract][Full Text] [Related]
24. pH-sensitive doxorubicin-loaded polymeric nanocomplex based on β-cyclodextrin for liver cancer-targeted therapy.
Yang T; Du G; Cui Y; Yu R; Hua C; Tian W; Zhang Y
Int J Nanomedicine; 2019; 14():1997-2010. PubMed ID: 30962684
[TBL] [Abstract][Full Text] [Related]
25. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
[TBL] [Abstract][Full Text] [Related]
26. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
Arabi L; Badiee A; Mosaffa F; Jaafari MR
J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
[TBL] [Abstract][Full Text] [Related]
27. Targeted doxorubicin delivery by chitosan-galactosylated modified polymer microbubbles to hepatocarcinoma cells.
Villa R; Cerroni B; Viganò L; Margheritelli S; Abolafio G; Oddo L; Paradossi G; Zaffaroni N
Colloids Surf B Biointerfaces; 2013 Oct; 110():434-42. PubMed ID: 23759384
[TBL] [Abstract][Full Text] [Related]
28. Uptake and release profiles of PEGylated liposomal doxorubicin nanoparticles: A comprehensive picture based on separate determination of encapsulated and total drug concentrations in tissues of tumor-bearing mice.
Wang H; Zheng M; Gao J; Wang J; Zhang Q; Fawcett JP; He Y; Gu J
Talanta; 2020 Feb; 208():120358. PubMed ID: 31816795
[TBL] [Abstract][Full Text] [Related]
29. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
[TBL] [Abstract][Full Text] [Related]
30. Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo.
Liu MC; Liu L; Wang XR; Shuai WP; Hu Y; Han M; Gao JQ
Int J Nanomedicine; 2016; 11():1395-412. PubMed ID: 27110110
[TBL] [Abstract][Full Text] [Related]
31. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
Li X; Ding L; Xu Y; Wang Y; Ping Q
Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
[TBL] [Abstract][Full Text] [Related]
32. A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor.
He X; Na MH; Kim JS; Lee GY; Park JY; Hoffman AS; Nam JO; Han SE; Sim GY; Oh YK; Kim IS; Lee BH
Mol Pharm; 2011 Apr; 8(2):430-8. PubMed ID: 21222482
[TBL] [Abstract][Full Text] [Related]
33. In Vitro Cell Toxicity and Intracellular Uptake of Doxorubicin Exposed as a Solution or Liposomes: Implications for Treatment of Hepatocellular Carcinoma.
Kullenberg F; Degerstedt O; Calitz C; Pavlović N; Balgoma D; Gråsjö J; Sjögren E; Hedeland M; Heindryckx F; Lennernäs H
Cells; 2021 Jul; 10(7):. PubMed ID: 34359887
[TBL] [Abstract][Full Text] [Related]
34. Hepatoma-targeting and pH-sensitive nanocarriers based on a novel D-galactopyranose copolymer for efficient drug delivery.
Ding Y; Han J; Tian B; Han J; Zhang J; Zheng H; Han Y; Pei M
Int J Pharm; 2014 Dec; 477(1-2):187-96. PubMed ID: 25455771
[TBL] [Abstract][Full Text] [Related]
35. A novel lactoferrin-modified stealth liposome for hepatoma-delivery of triiodothyronine.
Pireddu R; Pibiri M; Valenti D; Sinico C; Fadda AM; Simbula G; Lai F
Int J Pharm; 2018 Feb; 537(1-2):257-267. PubMed ID: 29294323
[TBL] [Abstract][Full Text] [Related]
36. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma.
Cheng Y; Zhao P; Wu S; Yang T; Chen Y; Zhang X; He C; Zheng C; Li K; Ma X; Xiang G
Int J Pharm; 2018 Jul; 545(1-2):261-273. PubMed ID: 29730175
[TBL] [Abstract][Full Text] [Related]
37. A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma.
Dai W; Fan Y; Zhang H; Wang X; Zhang Q; Wang X
Drug Deliv; 2015 Jan; 22(1):10-20. PubMed ID: 24735248
[TBL] [
